{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:16:05Z","timestamp":1789139765934,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11916-026-01559-4","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:07:39Z","timestamp":1789096059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Meaningful Measurable Quality Outcomes in Headache Management"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8596-9130","authenticated-orcid":false,"given":"Leon S.","family":"Moskatel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Smirnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"8","key":"1559_CR1","doi-asserted-by":"publisher","first-page":"033310242412673","DOI":"10.1177\/03331024241267309","volume":"44","author":"MF Peres","year":"2024","unstructured":"Peres MF, Sacco S, Pozo-Rosich P, Tassorelli C, Ahmed F, Burstein R, Ashina S, Uluduz D, Hus\u00f8y AK, Steiner TJ. Migraine is the most disabling neurological disease among children and adolescents, and second after stroke among adults: a call to action. Cephalalgia. 2024;44(8):03331024241267309.","journal-title":"Cephalalgia"},{"issue":"1","key":"1559_CR2","first-page":"1","volume":"11","author":"Guidelines for controlled trials of drugs in migraine","year":"1991","unstructured":"Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia. 1991;11(1):1\u201312. PMID: 2036663.","journal-title":"Cephalalgia"},{"issue":"24","key":"1559_CR3","doi-asserted-by":"publisher","first-page":"e2560","DOI":"10.1212\/WNL.0000000000207964","volume":"101","author":"CC Chiang","year":"2023","unstructured":"Chiang CC, Fang X, Horvath Z, Cadiou F, Urani A, Poh W, Narimatsu H, Cheng Y, Dodick DW. Simultaneous comparisons of 25 acute migraine medications based on 10 million users\u2019 self-reported records from a smartphone application. Neurology. 2023;101(24):e2560\u201370.","journal-title":"Neurology"},{"key":"1559_CR4","unstructured":"[Internet]. [cited 2026 Jul 18]. Available from: https:\/\/headaches.org\/resources\/headache-diary-keeping-a-diary-can-help-your-doctor-help-you\/"},{"issue":"5","key":"1559_CR5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1468-2982.2008.01555.x","volume":"28","author":"S Silberstein","year":"2008","unstructured":"Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, Wang SJ, Task Force of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28(5):484\u201395. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01555.x. Epub 2008 Feb 20. Erratum in: Cephalalgia. 2008;28(6):679. PMID: 18294250.","journal-title":"Cephalalgia"},{"key":"1559_CR6","doi-asserted-by":"publisher","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD,Goadsby PJ, Pozo-Rosich P, Wang SJ; International headache society clinical trials standingcommittee. guidelines of the international headache society for controlled trials of treatment of chronic migraine in adults. Cephalalgia. 2018 Apr;38(5):815-832. https:\/\/doi.org\/10.1177\/0333102418758283. Epub 2018 Mar 4. PMID: 29504482.","DOI":"10.1177\/0333102418758283"},{"key":"1559_CR7","doi-asserted-by":"publisher","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD,Goadsby PJ, Pozo-Rosich P, Wang SJ, Houle TT, Hoek TCVD, Martinelli D, Terwindt GM; International headache society clinical trials committee. guidelines of the internationalheadache society for controlled trials of preventive treatment of migraine attacks in episodicmigraine in adults. Cephalalgia. 2020;40(10):1026-1044. https:\/\/doi.org\/10.1177\/0333102420941839. Epub 2020 Jul 28. Erratum in: Cephalalgia. 2020;40(10):NP1. https:\/\/doi.org\/10.1177\/0333102420952270.","DOI":"10.1177\/0333102420952270"},{"issue":"9","key":"1559_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/NEJMoa2314577","volume":"391","author":"M Ashina","year":"2024","unstructured":"Ashina M, Phul R, Khodaie M, L\u00f6f E, Florea I. A monoclonal antibody to PACAP for migraine prevention. N Engl J Med. 2024;391(9):800\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"1559_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/head.14069","volume":"61","author":"JS McGinley","year":"2021","unstructured":"McGinley JS, Houts CR, Nishida TK, Buse DC, Lipton RB, Goadsby PJ, Dodick DW, Wirth RJ. Systematic review of outcomes and endpoints in preventive migraine clinical trials. Headache. 2021;61(2):253\u201362. https:\/\/doi.org\/10.1111\/head.14069. Epub 2021 Feb 18. PMID: 33600610; PMCID: PMC7986733.","journal-title":"Headache"},{"issue":"1","key":"1559_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12883-021-02085-z","volume":"21","author":"PL Ferreira","year":"2021","unstructured":"Ferreira PL, Luzeiro I, Lopes M, Jorge A, Silva B, Ferreira L. Validity and reliability of the Portuguese version of the modified Migraine Disability Assessment. BMC Neurol. 2021;21(1):58.","journal-title":"BMC Neurol"},{"issue":"1","key":"1559_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12883-020-01646-y","volume":"20","author":"D Rodr\u00edguez-Almagro","year":"2020","unstructured":"Rodr\u00edguez-Almagro D, Achalandabaso A, Rus A, Obrero-Gait\u00e1n E, Zagalaz-Anula N, Lomas-Vega R. Validation of the Spanish version of the migraine disability assessment questionnaire (MIDAS) in university students with migraine. BMC Neurol. 2020;20(1):67.","journal-title":"BMC Neurol"},{"issue":"1","key":"1559_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s41669-017-0034-3","volume":"2","author":"T Oikonomidi","year":"2018","unstructured":"Oikonomidi T, Vikelis M, Artemiadis A, Chrousos GP, Darviri C. Reliability and validity of the Greek migraine disability assessment (MIDAS) questionnaire. PharmacoEconomics-Open. 2018;2(1):77\u201385.","journal-title":"PharmacoEconomics-Open"},{"issue":"7","key":"1559_CR13","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/head.14592","volume":"63","author":"A Nagri","year":"2023","unstructured":"Nagri A, Patel M, Mwansisya T, Adebayo PB. Development and initial validation of the Kiswahili version of the Migraine Disability Assessment (MIDAS-K) questionnaire. Headache: J Head Face Pain. 2023;63(7):880\u20138.","journal-title":"Headache: J Head Face Pain"},{"issue":"4","key":"1559_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1526-4610.2003.03069.x","volume":"43","author":"M Iigaya","year":"2003","unstructured":"Iigaya M, Sakai F, Kolodner KB, Lipton RB, Stewart WF. Reliability and validity of the Japanese migraine disability assessment (MIDAS) questionnaire. Headache: J Head Face Pain. 2003;43(4):343\u201352.","journal-title":"Headache: J Head Face Pain"},{"issue":"1","key":"1559_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12883-022-02774-3","volume":"22","author":"A Blumenfeld","year":"2022","unstructured":"Blumenfeld A, Ettrup A, Hirman J, Ebert B, Cady R. Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab. BMC Neurol. 2022;22(1):251.","journal-title":"BMC Neurol"},{"key":"1559_CR16","doi-asserted-by":"publisher","unstructured":"Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache. 2000;40(3):204\u2009\u2013\u200915. https:\/\/doi.org\/10.1046\/j.1526-4610.2000.00030.x. PMID: 10759923.","DOI":"10.1046\/j.1526-4610.2000.00030.x"},{"key":"1559_CR17","doi-asserted-by":"publisher","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahl\u00f6f CG, Dowson A, Tepper S. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12(8):963\u2009\u2013\u200974. https:\/\/doi.org\/10.1023\/a:1026119331193. PMID: 14651415.","DOI":"10.1023\/a:1026119331193"},{"issue":"1","key":"1559_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/head.13701","volume":"60","author":"CR Houts","year":"2020","unstructured":"Houts CR, Wirth RJ, McGinley JS, Gwaltney C, Kassel E, Snapinn S, Cady R. Content Validity of HIT-6 as a Measure of Headache Impact in People With Migraine: A Narrative Review. Headache. 2020;60(1):28\u201339. https:\/\/doi.org\/10.1111\/head.13701 . Epub 2019 Dec 6. PMID: 31811654; PMCID: PMC7003926.","journal-title":"Headache"},{"key":"1559_CR19","doi-asserted-by":"crossref","unstructured":"Guidelines for controlled trials of drugs in migraine. First edition. International headache society committee on clinical trials in migraine. Cephalalgia. 1991 Feb;11(1):1-12. PMID: 2036663","DOI":"10.1046\/j.1468-2982.1991.1101001.x"},{"issue":"6","key":"1559_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD,Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical TrialsStanding Committee. Guidelines of the International Headache Society for controlled trials ofacute treatment of migraine attacks in adults: Fourth edition. Cephalalgia. 2019 May;39(6):687-710. doi: 10.1177\/0333102419828967. Epub 2019 Feb 26. PMID: 30806518; PMCID:PMC6501455.","journal-title":"Cephalalgia"},{"key":"1559_CR21","doi-asserted-by":"crossref","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015 May;35(6):478-88.","DOI":"10.1177\/0333102414547138"},{"issue":"8","key":"1559_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/pm\/pnae020","volume":"25","author":"LS Moskatel","year":"2024","unstructured":"Moskatel LS, Graber-Naidich A, He Z, Zhang N. Long-term persistence to onabotulinumtoxinA to prevent chronic migraine: results from 11 years of patient data from a tertiary headache center. Pain Med. 2024;25(8):487\u201392.","journal-title":"Pain Med"},{"key":"1559_CR23","doi-asserted-by":"publisher","first-page":"251581632513889","DOI":"10.1177\/25158163251388920","volume":"8","author":"T Garrido Hern\u00e1ndez","year":"2025","unstructured":"Garrido Hern\u00e1ndez T, Andrade Zumarraga LA, Perea Justicia P, Mart\u00ednez Sim\u00f3n J, Arjona Padillo A. Long-term persistence of anti-calcitonin gene-related peptide monoclonal antibodies in treatment-resistant migraine: A three-year follow-up study in Spain. Cephalalgia Rep. 2025;8:25158163251388920.","journal-title":"Cephalalgia Rep"},{"issue":"1","key":"1559_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-023-01636-8","volume":"24","author":"IVL Charleston","year":"2023","unstructured":"Charleston IVL, Talon B, Sullivan C, Anderson C, Kymes S, Regnier SA, Soni-Brahmbhatt S, Nahas SJ. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study. J Headache Pain. 2023;24(1):101.","journal-title":"J Headache Pain"},{"issue":"1","key":"1559_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s10194-022-01521-w","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study. J Headache Pain. 2022;23(1):153.","journal-title":"J Headache Pain"},{"issue":"1","key":"1559_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s41687-024-00813-w","volume":"8","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Awad SF, Rae-Espinoza H, Regnier SA, Lee XY, Goadsby PJ. Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial. J Patient-Reported Outcomes. 2024;8(1):146.","journal-title":"J Patient-Reported Outcomes"},{"issue":"1","key":"1559_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12883-023-03302-7","volume":"23","author":"N Siersb\u00e6k","year":"2023","unstructured":"Siersb\u00e6k N, Kilsdal L, Jervelund C, Antic S, Bendtsen L. Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine. BMC Neurol. 2023;23(1):254.","journal-title":"BMC Neurol"},{"issue":"8","key":"1559_CR28","doi-asserted-by":"publisher","first-page":"818","DOI":"10.18553\/jmcp.2022.28.8.818","volume":"28","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene\u2013related peptide inhibitors vs other preventive migraine treatments in the United States. J Managed Care Specialty Pharm. 2022;28(8):818\u201329.","journal-title":"J Managed Care Specialty Pharm"},{"key":"1559_CR29","doi-asserted-by":"crossref","unstructured":"Cowan R, Stark-Inbar A, Rabany L, Harris D, Vizel M, Ironi A, Vieira JR, Galen M, Treppendahl C, Raffaelli B, Thuraiaiyah J, Christensen RH, Al-Khazali HM, Ashina H, Snellman J, Maio\u2010Twofoot T, Ashina M. Clinical benefits and economic cost-savings of remote electrical neuromodulation (REN) for migraine prevention. J Med Economics European J Neurol. 2023 2025;26(1):656\u201364.","DOI":"10.1080\/13696998.2023.2205751"},{"key":"1559_CR30","doi-asserted-by":"crossref","unstructured":"Raffaelli B, Thuraiaiyah J, Christensen RH, Al-Khazali HM, Ashina H, Snellman J, Maio-Twofoot T ,Ashina M. Impact of erenumab on comorbid depression, anxiety, and sleep quality in migraine: A Registry for migraine (REFORM) study. Eur J Neurol. 2025 Nov;32(11):e70402.","DOI":"10.1111\/ene.70402"},{"key":"1559_CR31","doi-asserted-by":"crossref","unstructured":"Iannone LF, Boccalini A, Lo Castro F, Brovia D, Romozzi M, Vernieri F, Altamura C, Gu\u00e9rzoni S. Effect of atogepant on sleep quality and sleep-related adverse events in adult patients with migraine: A prospective observational 12-week study: LF Iannone et al. CNS drugs. 2025 Oct10:1-4.","DOI":"10.1007\/s40263-025-01235-y"},{"key":"1559_CR32","doi-asserted-by":"crossref","unstructured":"Van Der Donckt J, Vandenbussche N, De Brouwer M, Steenwinckel B, Stojchevska M, Ongenae F,Paemeleire K, Van Hoecke S. Analysis of free-living daytime movement in patients with migrainewith access to acute treatment. The Journal of Headache and Pain. 2025 Feb 13;26(1):33.","DOI":"10.1186\/s10194-025-01971-y"},{"issue":"9","key":"1559_CR33","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/head.14389","volume":"62","author":"R Croop","year":"2022","unstructured":"Jantzen FT, Chaudhry BA, Younis S, N\u00f8rgaard I, Cullum CK, Do TP, Beier D, Amin FM. Averagesteps per day as marker of treatment response with anti-CGRP mAbs in adults with chronicmigraine: a pilot study. Scientific Reports. 2024 Aug 5;14(1):18068.","journal-title":"Headache: J Head Face Pain"},{"key":"1559_CR34","doi-asserted-by":"crossref","unstructured":"Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A, Coric V, Lipton RB. Zavegepantnasal spray for the acute treatment of migraine: a phase 2\/3 double-blind, randomized,placebo-controlled, dose-ranging trial. Headache: The Journal of Head and Face Pain. 2022 Oct;62(9):1153-63.","DOI":"10.1111\/head.14389"},{"issue":"19","key":"1559_CR35","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887\u201398.","journal-title":"JAMA"},{"issue":"5","key":"1559_CR36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17581869.2025.2494494","volume":"15","author":"L Pellesi","year":"2025","unstructured":"Pellesi L, Jedie B, Barhum F, Al-Abdullah S, Martelletti P, Xiao Z. Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. Pain Manage. 2025;15(5):279\u201384.","journal-title":"Pain Manage"},{"issue":"4","key":"1559_CR37","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1097\/JOM.0000000000002801","volume":"65","author":"DC Buse","year":"2023","unstructured":"Buse DC, Nahas SJ, Armand CE, Reed ML, Fanning KM, Adams AM, Lipton RB. Optimized acute treatment of migraine is associated with greater productivity in people with migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study. J Occup Environ Med. 2023;65(4):e261\u20138.","journal-title":"J Occup Environ Med"},{"issue":"7","key":"1559_CR38","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1468-2982.2008.01786.x","volume":"29","author":"RB Lipton","year":"2009","unstructured":"Lipton RB, Kolodner K, Bigal ME, Valade D, L\u00e1inez MJ, Pascual J, Gendolla A, Bussone G, Islam N, Albert K, Parsons B. Validity and reliability of the migraine-treatment optimization questionnaire. Cephalalgia. 2009;29(7):751\u20139.","journal-title":"Cephalalgia"},{"issue":"4","key":"1559_CR39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/head.14706","volume":"64","author":"MH Hazewinkel","year":"2024","unstructured":"Hazewinkel MH, Gfrerer L, Ashina S, Austen WG, Klassen AF, Pusic A, Kaur MN. Readability analysis and concept mapping of PROMs used for headache disorders. Headache: J Head Face Pain. 2024;64(4):410\u201323.","journal-title":"Headache: J Head Face Pain"},{"issue":"8","key":"1559_CR40","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/j.1526-4610.2009.01587.x","volume":"50","author":"MJ Drescher","year":"2010","unstructured":"Drescher MJ, Alpert EA, Zalut T, Torgovicky R, Wimpfheimer Z. Prophylactic etoricoxib is effective in preventing Yom Kippur headache: A placebo-controlled double\u2010blind and randomized trial of prophylaxis for ritual fasting headache. Headache: J Head Face Pain. 2010;50(8):1328\u201334.","journal-title":"Headache: J Head Face Pain"},{"issue":"4","key":"1559_CR41","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1526-4610.2011.01993.x","volume":"52","author":"MJ Drescher","year":"2012","unstructured":"Drescher MJ, Wimpfheimer Z, Abu Khalef S, Gammaitoni A, Shehadeh N, Torgovicky R. Prophylactic etoricoxib is effective in preventing first of Ramadan headache: a placebo-controlled double\u2010blind and randomized trial of prophylactic etoricoxib for ritual fasting headache. Headache: J Head Face Pain. 2012;52(4):573\u201381.","journal-title":"Headache: J Head Face Pain"},{"issue":"7","key":"1559_CR42","doi-asserted-by":"publisher","first-page":"033310242513559","DOI":"10.1177\/03331024251355947","volume":"45","author":"T Alsaadi","year":"2025","unstructured":"Alsaadi T, Suliman R, Yang J, Agarwal E, Fullerton T, Chou DE, Whalen E, El Jadam C, Al Qaisi I, Amin Y, Alkhateri A. A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75\u00a0mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine. Cephalalgia. 2025;45(7):03331024251355947.","journal-title":"Cephalalgia"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-026-01559-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:02:45Z","timestamp":1789138965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-026-01559-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1559"],"URL":"https:\/\/doi.org\/10.1007\/s11916-026-01559-4","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Moskatel receives royalties from CRC Press, is a subivestigator on a clinical trial by Ipsen Pharmaceuticals and participated in an advisory board by Amneal Pharmaceuticals. Dr. Smirnoff has received grant support from NeuroNext, and sub-investigator support from Abbvie, Ipsen and Merz. Dr. Smirnoff has received honoraria for continuing medical education (CME) activities from the American Headache Society.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The articles utilized in this review were all previously published and complied with applicable ethical standards for studies\/experiments with human or animal subjects.","order":2,"name":"Ethics","label":"Human and Animal Rights","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"120"}}